Name: CHEMOMAB THERAPEUTICS LTD (CMMB) Stock
Brand: CHEMOMAB THERAPEUTICS LTD
Rating: 4 (3 reviews)

CMMB Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chemomab Therapeutics Ltd.

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

4 days ago - By: Chemomab Therapeutics Ltd.

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

12 days ago - By: Chemomab Therapeutics Ltd.

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

16 days ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Zacks Investment Research - Mentions: GES PARR

Best Momentum Stocks to Buy for Oct. 23

16 days ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Chemomab Therapeutics

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

a month ago - By: Chemomab Therapeutics

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

a month ago - By: Zacks Investment Research - Mentions: ALKS AVDL CSTL

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

2 months ago - By: Zacks Investment Research - Mentions: ANIP ESPR EVO

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

2 months ago - By: Zacks Investment Research - Mentions: ADCT ZTS ALLO

Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain

2 months ago - By: Zacks Investment Research - Mentions: SNY TEVA ALLO

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

2 months ago - By: Zacks Investment Research - Mentions: CDTX ALLO AKRO

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

4 months ago - By: Chemomab Therapeutics

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Benzinga - Mentions: ACET CLDX ALC BLRX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

4 months ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Chemomab Therapeutics

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Chemomab Therapeutics

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

5 months ago - By: Chemomab Therapeutics

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

6 months ago - By: Chemomab Therapeutics

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

6 months ago - By: Chemomab Therapeutics

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

6 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN KURA

KURA Stock Rises More Than 15% This Past Week: Here's Why

6 months ago - By: Zacks Investment Research - Mentions: LXRX TPST

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

6 months ago - By: Chemomab Therapeutics

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

6 months ago - By: Zacks Investment Research - Mentions: MRK LXRX

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

6 months ago - By: Zacks Investment Research - Mentions: REGN LXRX NTLA

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

6 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN CADL

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

6 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN RCKT